Federated Hermes’s Cerevel Therapeutics Holdings CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-1,214,972
Closed -$38.6M – 2230
2023
Q2
$38.6M Sell
1,214,972
-710,000
-37% -$21.8M 0.1% 252
2023
Q1
$47M Sell
1,924,972
-942,479
-33% -$27.7M 0.12% 218
2022
Q4
$90.4M Sell
2,867,451
-445,882
-13% -$12.6M 0.25% 82
2022
Q3
$93.6M Buy
3,313,333
+200,000
+6% +$5.96M 0.27% 79
2022
Q2
$82.3M Hold
3,113,333
– – 0.22% 108
2022
Q1
$109M Hold
3,113,333
– – 0.25% 104
2021
Q4
$101M Hold
3,113,333
– – 0.19% 151
2021
Q3
$91.8M Buy
3,113,333
+1,163,333
+60% +$32.7M 0.17% 162
2021
Q2
$50M Hold
1,950,000
– – 0.09% 283
2021
Q1
$26.8M Buy
1,950,000
+998,300
+105% +$14.6M 0.05% 424
2020
Q4
$15.8M Buy
+951,700
New +$12.4M 0.03% 530

Other funds holding CERE

Federated Hermes's CERE Position: Q3 2023 in Review

Federated Hermes sold out of Cerevel Therapeutics Holdings (CERE) in Q3 2023, closing a stake of 1,214,972 shares — an estimated $38.6M sold.

Federated Hermes first reported a position in CERE in Q4 2020 and held it in 11 quarters. The position peaked at $109M in Q1 2022. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Federated Hermes reported no remaining Cerevel Therapeutics Holdings position as of Q3 2023 after selling out during the quarter.
  • Federated Hermes sold 1,214,972 Cerevel Therapeutics Holdings shares in Q3 2023, an estimated $38.6M.
  • Federated Hermes first reported a position in Cerevel Therapeutics Holdings in Q4 2020 and held it in 11 quarters.
  • Federated Hermes's Cerevel Therapeutics Holdings position peaked at $109M in Q1 2022.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings as of Q3 2023.

Based on Federated Hermes's 13F filing for Q3 2023, filed 13 Nov 2023.